Clinical Outcomes and Prognosis Factors of Nivolumab Plus Chemotherapy or Multitarget Tyrosine Kinase Inhibitor in Multi-Line Therapy for Recurrent Hepatitis B Virus-Related Hepatocellular Carcinoma: A Retrospective Analysis

Background: This study investigates the potential predictors of nivolumab plus chemotherapy or multitarget tyrosine kinase inhibitor (TKI) treatment response in patients with recurrent hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). Methods: Patients with recurrent hepatitis B virus-...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Chao, An, Li, Cheng, Ying, Luo, Xianwen, Li, Zixiong, Liu, Xiufeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7479184/
https://www.ncbi.nlm.nih.gov/pubmed/32983970
http://dx.doi.org/10.3389/fonc.2020.01404

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7479184/
https://www.ncbi.nlm.nih.gov/pubmed/32983970
http://dx.doi.org/10.3389/fonc.2020.01404

Ejemplares similares